Currently, there is a recognized causal link between infectious diseases such as influenza, acute respiratory viral infections, and COVID-19, and the onset or worsening of various chronic and concurrent health conditions. These include, but are not limited to, cardiac disorders, both type I and II diabetes, bronchial asthma, chronic obstructive pulmonary disease, and injuries affecting the brain, chest, and lungs. Notably, complications arising from transthoracic lung biopsies, such as tumor-like formations and pneumothorax, have been observed. An in-depth analysis was conducted on complications following transthoracic biopsies, particularly those monitored via computer tomography. This involved a comprehensive review of existing scientific literature on the subject matter. It is imperative to underscore the critical need for appropriate pharmacotherapy to manage these complications, emphasizing the necessity of essential medications within the framework of legal interactions among doctors, patients, pharmacists, and lawyers. This research is inherently multidisciplinary, bridging the fields of medical science, pharmacology, and legal studies. The technique of conducting transthoracic biopsies with the guidance of computer tomography is meticulously detailed within this study. The discussion extends to the method's benefits, inherent risks, and unique characteristics, highlighting its utility in diagnosing and managing lung-related pathologies. Despite the potential for complications, this method is portrayed as largely safe, minimally invasive, and without significant adverse outcomes. It stands out as a promising avenue for future investigations, especially in the accurate diagnosis and management of lung diseases. This conclusion not only reflects the efficacy and safety of the transthoracic biopsy method when performed under computed tomography but also calls for ongoing research to further optimize and understand its application in clinical practice. The interplay between advanced diagnostic techniques, effective pharmacotherapy, and the legal framework governing healthcare practices forms a crucial nexus for enhancing patient care and outcomes in the face of complex respiratory diseases and associated conditions.